Essex Bio-Technology Limited (HKG:1061)

Market Cap	2.05B +32.1%
Revenue (ttm)	1.81B +8.6%
Net Income	318.09M +3.5%
EPS	0.56 +5.5%
Shares Out	567.01M
PE Ratio	6.45
Forward PE	n/a
Dividend	0.14 (3.78%)
Ex-Dividend Date	May 28, 2026

Volume	474,000
Average Volume	557,375
Open	3.750
Previous Close	3.700
Day's Range	3.610 - 3.750
52-Week Range	3.320 - 6.120
Beta	-0.14
RSI	43.86
Earnings Date	Mar 23, 2026

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 1,426
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1061

Financial Performance

In 2025, Essex Bio-Technology's revenue was 1.81 billion, an increase of 8.62% compared to the previous year's 1.67 billion. Earnings were 318.09 million, an increase of 3.54%.